alexa Tapentadol Prolonged Release Improves Analgesia, Functi
ISSN: 2167-0846

Journal of Pain & Relief
Open Access

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Research Article

Tapentadol Prolonged Release Improves Analgesia, Functional Impairment, and Quality of Life in Patients With Chronic Pain Who Have Previously Received Oxycodone/Naloxone

Kern KU1, Krings D2, and Waldmann-Rex S2*

1Institute for Pain Medicine/Pain Practice Wiesbaden, Germany

2Medical Affairs, German Division, Grünenthal GmbH, Aachen, Germany

*Corresponding Author:
Susanne Waldmann-Rex
Medical Affairs, German Division, Grünenthal GmbH
Geschäftsbereich Deutschland, Aachen
Germany
Tel: +49241569-1981
E-mail: [email protected]

Received date: November 28, 2016; Accepted date: November 29, 2016; Published date: January 16, 2017

Citation: Kern KU, Krings D, Waldmann-Rex S (2017) Tapentadol Prolonged Release Improves Analgesia, Functional Impairment and Quality of Life in Patients with Chronic Pain who have Previously Received Oxycodone/Naloxone. J Pain Relief 6: 281. doi: 10.4172/2167-0846.1000281

Copyright: ©2017 Kern KU et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

 

Abstract

Background: This subgroup analysis of a prospective, non-interventional study involving general practitioners/ internists evaluated tapentadol prolonged release (PR) in patients who previously received oxycodone/naloxone. Methods: This non-interventional study, which had a 3-month observation period, included 5002 patients. Data from a subgroup of patients previously treated with oxycodone/naloxone (n=382) were included in this analysis. Results: Back pain was the most common cause of pain, and mixed pain (nociceptive and neuropathic) predominated. Oxycodone/naloxone pretreatment was most commonly combined with non-opioids (78.3%) or coanalgesics (56.0%). The most common reasons for starting tapentadol PR were insufficient analgesia (87.4%) and impaired quality of life (70.2%). Switching to tapentadol PR (final average daily dose, 252.9 mg) resulted in a mean pain reduction of 3.41 points on an 11-point numerical rating scale (baseline, 7.29 ± 1.40; end of observation, 3.88 ± 1.86; descriptive P value ≤ 0.001; n=373). The percentage of patients who did not require additional analgesics (i.e., those on tapentadol PR monotherapy) increased from 24.6% at the start of treatment to 33.5% at the final visit. Coanalgesic use also decreased from the start of treatment to the final visit (antidepressants: 46.6% to 39.4%; anticonvulsants: 24.6% to 15.9%). Significant improvements were achieved in pain-related functional impairment and Short Form-12 summary scores. Tapentadol PR was well tolerated. Conclusion: Patients who previously received oxycodone/naloxone benefit from tapentadol PR therapy; clinically relevant improvements in analgesia, functionality, and quality of life were documented. Furthermore, analgesic comedication could be reduced during tapentadol PR treatment, reducing medication burden and potentially leading to improved compliance.

Keywords

Share This Page

Additional Info

Loading
Loading Please wait..
 
Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

Agri, Food, Aqua and Veterinary Science Journals

Dr. Krish

[email protected]

1-702-714-7001 Extn: 9040

Clinical and Biochemistry Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Business & Management Journals

Ronald

[email protected]

1-702-714-7001Extn: 9042

Chemical Engineering and Chemistry Journals

Gabriel Shaw

[email protected]

1-702-714-7001 Extn: 9040

Earth & Environmental Sciences

Katie Wilson

[email protected]

1-702-714-7001Extn: 9042

Engineering Journals

James Franklin

[email protected]

1-702-714-7001Extn: 9042

General Science and Health care Journals

Andrea Jason

[email protected]

1-702-714-7001Extn: 9043

Genetics and Molecular Biology Journals

Anna Melissa

[email protected]

1-702-714-7001 Extn: 9006

Immunology & Microbiology Journals

David Gorantl

[email protected]

1-702-714-7001Extn: 9014

Informatics Journals

Stephanie Skinner

[email protected]

1-702-714-7001Extn: 9039

Material Sciences Journals

Rachle Green

[email protected]

1-702-714-7001Extn: 9039

Mathematics and Physics Journals

Jim Willison

[email protected]

1-702-714-7001 Extn: 9042

Medical Journals

Nimmi Anna

[email protected]

1-702-714-7001 Extn: 9038

Neuroscience & Psychology Journals

Nathan T

[email protected]

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

John Behannon

[email protected]

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

[email protected]

1-702-714-7001 Extn: 9042

 
© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
adwords